Posts

Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer; Next-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index

Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.

Press Release: Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer

Propella Therapeutics, Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.